This sub-committee was responsible for the National Immunisation Handbook (the Handbook)—the Government-produced national clinical guidelines aimed at all health professionals. These clinical guidelines were not directly connected

to Government vaccine funding decisions. In 1997, the Government decided to bring this advisory function inside the Department of Health and Ageing (DoHA) and remove it from under NHMRC governance by creating the Australian Technical Advisory Group on Immunisation (ATAGI) under the Minister for Health, with essentially the same functions as the former NHMRC sub-committee. However, the provision of advice function was narrowed to provide confidential advice to the Minister. In 2005, the Government introduced legislation to bring vaccine funding applications into the same transparent and predictable mechanism that had been used successfully for drugs. The Australian Pharmaceutical JQ1 manufacturer Benefits Scheme (PBS) has a long history of acceptability to Government and to industry, with an effective methodology to minimise price and to standardise a decision framework using cost-effectiveness evaluation based on a price per http://www.selleckchem.com/products/dorsomorphin-2hcl.html disability- or quality-adjusted life

year saved. These new arrangements have produced a high quality policy framework that has supported the introduction and public funding of many new vaccines. Ultimately, however, as with all countries, the capacity to pay regardless of future health savings is an immediate issue for governments that is constrained by the availability of funds drawn from the public purse that must support the full range of government commitments, both within and beyond the health

sector. The terms of reference of ATAGI Liothyronine Sodium are to: • provide technical advice to the Minister for Health and Ageing on the medical administration of vaccines available in Australia, including those on the NIP; There are a number of collaborating agencies that interact with ATAGI in the provision of advice and the formulation of policy and funding decisions (Fig. 2). The National Centre for Immunisation Research and Surveillance (NCIRS) of vaccine-preventable diseases, funded by the Australian Government, plays a major role in supporting ATAGI and its working parties, described below. Formal responsibility for vaccine safety monitoring resides with the ADRAC of the Therapeutic Goods Administration. The PBAC plays a key role, described below, in making vaccine funding recommendations to Government, based on the manufacturer’s submission, ATAGI advice and other expert health economic inputs. The NIC chaired by the Australian Government, is comprised of State and Territory Government immunisation directors plus members from the medical and general practice community, NCIRS and consumers.